Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026

• Mirum Pharmaceuticals has been a large victor successful 2025 acknowledgment to the occurrence of its flagship product, Livmarli.

• Livmarli should proceed to summation momentum successful 2026.

• Good quality from a Phase 2 survey of volixibat successful treating superior sclerosing cholangitis could besides supply a catalyst for Mirum adjacent year.

• 10 stocks we similar amended than Mirum Pharmaceuticals ›

Some stocks execute exceptionally good and garner tons of attraction for it. They mightiness adjacent prime up drawback nicknames similar the "Magnificent Seven" stocks on the way. Other stocks, though, present tremendous gains, yet they stay nether the radar for astir investors.

Mirum Pharmaceuticals (NASDAQ: MIRM) is an fantabulous illustration of the second category. This mid-cap banal has soared astir 70% successful 2025. I foretell Mirum volition beryllium an adjacent bigger victor successful 2026.

Although Mirum has 3 approved products connected the market, 1 of them stands retired arsenic the company's superior maturation driver. Sales for Livmarli soared 56% year-over-year successful the 3rd 4th of 2025 to $92.2 million. The cause accounted for astir 69% of Mirum's full income successful the quarter.

The U.S. Food and Drug Administration (FDA) archetypal approved Livmarli successful September 2021 for the attraction of cholestatic pruritus (itching) successful patients with Alagille syndrome. Only betwixt 4,000 and 5,500 patients successful the U.S. and the European Union person Alagille syndrome, a familial upset successful which bile builds up successful the liver owed to the lack of capable bile ducts.

In 2024, Mirum secured 2 further FDA approvals for Livmarli successful a related upset – 1 for treating patients aged 5 years oregon older with Progressive Familial Intrahepatic Cholestasis (PFIC) and the different expanding the statement to see patients with PFIC aged 12 months oregon older. In April of this year, Mirum added FDA approvals for a tablet mentation of Livmarli successful some Alagille syndrome and PFIC.

The company's 2 bile acerb medicines – Cholbam and Ctexli – besides proceed to bask coagulated commercialized success. Combined income for these 2 drugs jumped 31% year-over-year successful Q3 to $40.8 million.

I expect Mirum's momentum volition accelerate adjacent year. Livmarli is simply a cardinal crushed down my optimism. In my view, the availability of a tablet formulation of the cause volition boost sales. Peter Radovich, Mirum's president and COO, stated during the Q3 net telephone that the institution is already seeing a "very encouraging" uptake for Livmarli tablets.

Mirum believes that Livmarli has the imaginable to make yearly income exceeding $1 billion. I agree. But it's not the lone imaginable blockbuster cause successful the company's portfolio. Two pipeline candidates, voloxibat and MRM-3379, could besides beryllium monolithic winners.